Moctezuma-Velázquez C, Low G, Mourtzakis M, Ma M, Burak KW, Tandon P, Montano-Loza AJ

Language: English
References: 32
Page: 615-623
PDF size: 233.97 Kb.

ABSTRACT

Introduction and aim. Sarcopenia is an independent predictor of mortality in cirrhosis. Hypogonadism is co has been associated with sarcopenia in non-cirrhotic chronic liver disease populations. The aim of this study i copenia is associated with low testosterone levels in patients with cirrhosis. Material and methods. This is ysis of prospectively collected data of 211 cirrhotic patients undergoing evaluation for liver transplantation. Sa by computed tomography (CT) scan using specific cutoffs of the 3rd lumbar vertebra skeletal muscle index (L3 sterone levels were obtained in all patients. Results. Of the 211 patients, sarcopenia was noted in 94 (45%) were lower in sarcopenic patients (10.7 ± 1.1 vs. 13.7 ± 1.4 nmol/L, p = 0.03) and hypotestosteronemia was too (34 vs. 16%, p = 0.004). In males, those with sarcopenia had lower testosterone levels (14.6 ± 1.4 ‹. 2 and the corresponding frequency of hypotestosteronemia (42 vs. 19%, p = 0.006) was also higher. There wer ences in female patients. There was a weak correlation between L3 SMI and testosterone levels (r 0.37, p ‹ 0. regression analysis including sex, body mass index (BMI), hypotestosteronemia, MELD and etiology of cirrhosi onemia (RR 2.76, p = 0.005) and BMI (RR 0.88, p ‹ 0.001) were independently associated with sarcopenia. tosterone levels are associated with sarcopenia in male cirrhotic patients. The potential therapeutic effect of te sarcopenia in these patients warrants evaluation in future trials.

REFERENCES

1. Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol 2016; 65: 1232-44.

2. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, Sawyer MB. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10: 166-73.

3. Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CM, Sawyer MB, Beaumont C, Esfandiari N, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle 2016; 7: 126-35.

4. Montano-Loza AJ. Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroenterol 2014; 20: 8061-71.

5. Basualto-Alarcon C, Varela D, Duran J, Maass R, Estrada M. Sarcopenia and androgens: a link between pathology and treatment. Front Endocrinol 2014; 5: 217.

6. von Haehling S. The wasting continuum in heart failure: from sarcopenia to cachexia. Proc Nutr Soc 2015; 74: 367-77.

7. Chang D, Joseph DJ, Ebert MA, Galvao DA, Taaffe DR, Denham JW, Newton RU, et al. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. J Med Imaging Radiat Oncol 2014; 58: 223-8.

8. Gluud C. Serum testosterone concentrations in men with alcoholic cirrhosis: background for variation. Metabolism 1987; 36: 373-8.

9. Van Thiel DH, Kumar S, Gavaler JS, Tarter RE. Effect of liver transplantation on the hypothalamic-pituitary-gonadal axis of chronic alcoholic men with advanced liver disease. Alcohol Clin Exp Res 1990; 14: 478-81.

10. Sinclair M, Grossmann M, Gow PJ, Angus PW. Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol 2015; 30: 244-51.

11. Sinclair M, Gow PJ, Grossmann M, Shannon A, Hoermann R, Angus PW. Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the model for end-stage liver disease score. Liver Transpl 2016; 22: 1482-90.

12. Giusto M, Lattanzi B, Albanese C, Galtieri A, Farcomeni A, Giannelli V, Lucidi C, et al. Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. Eur J Gastroenterol Hepatol 2015; 27: 328-34.

13. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539-47.

14. Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, Beaumont C, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl 2014; 20: 640-8.

15. van Vugt JL, Levolger S, de Bruin RW, van Rosmalen J, Metselaar HJ, JN IJ. Systematic Review and Meta-Analysis of the Impact of Computed Tomography-Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation. Am J Transplant 2016; 16: 2277-92.

16. Carey EJ, Lai JC, Wang CW, Dasarathy S, Lobach I, Montano- Loza AJ, Dunn MA. A multi-center study to define sarcopenia in patients with end-stage liver disease: From the Fitness, Life Enhancement, and Exercise in Liver Transplantation (FLEXIT) Consortium. Liver Transpl 2017; 23: 625-33.

17. Sinclair M, Grossmann M, Angus PW, Hoermann R, Hey P, Scodellaro T, Gow PJ. Low testosterone as a better predictor of mortality than sarcopenia in men with advanced liver disease. J Gastroenterol Hepatol 2016; 31: 661-7.

18. Zanandrea V, Giua R, Costanzo L, Vellas B, Zamboni M, Cesari M. Interventions against sarcopenia in older persons. Curr Pharm Des 2014; 20: 5983-6006.

19. Dasarathy S. Cause and management of muscle wasting in chronic liver disease. Curr Opin Gastroenterol 2016; 32: 159-65.

20. Zenith L, Meena N, Ramadi A, Yavari M, Harvey A, Carbonneau M, Ma M, et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12: 1920-6 e1922.

21. Sinclair M, Grossmann M, Hoermann R, Angus PW, Gow PJ. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. J Hepatol 2016; 65: 906-13.

22. Yurci A, Yucesoy M, Unluhizarci K, Torun E, Gursoy S, Baskol M, Guven K, et al. Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis. Clin Res Hepatol Gastroenterol 2011; 35: 845-54.

23. Santos LA, Romeiro FG. Diagnosis and Management of Cirrhosis- Related Osteoporosis. Biomed Res Int 2016; 2016: 1423462.

24. Tanaka K, Sakai H, Hashizume M, Hirohata T. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 2000; 60: 5106-10.

25. Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993; 53: 790- 4.

26. Ganne-Carrie N, Chastang C, Uzzan B, Pateron D, Trinchet JC, Perret G, Beaugrand M. Predictive value of serum sex hormone binding globulin for the occurrence of hepatocellular carcinoma in male patients with cirrhosis. J Hepatol 1997; 26: 96-102.

27. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002; 50 (Suppl. 1): i1-9.

28. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med 2016; 374: 611-24.

29. Anderson JL, May HT, Lappe DL, Bair T, Le V, Carlquist JF, Muhlestein JB. Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. Am J Cardiol 2016; 117: 794-9.

30. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-23.

31. Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A Reappraisal of Testosterone’s Binding in Circulation: Physiological and Clinical Implications. Endocr Rev 2017; Doi: 10.1210/er.2017-00025 [Epub ahead of print].

32. Brandhorst G, Streit F, Kratzsch J, Schiettecatte J, Roth HJ, Luppa PB, Körner A, et al. Multicenter evaluation of a new automated electrochemiluminescence immunoassay for the quantification of testosterone compared to liquid chromatography tandem mass spectrometry. Clin Biochem 2011; 44: 264-7.